Compounds > fulvestrant
Page last updated: 2024-08-26

fulvestrant and metoprolol

fulvestrant has been researched along with metoprolol in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bloch, W; Brixius, K; Hoyer, H; Ladage, D; Malan, D; Schwinger, RH; Steingen, C; Wesseling, A1
Büssemaker, E; Hagedorn, C; Hausberg, M; Hillebrand, U; Kliche, K; Lang, D; Oberleithner, H; Pavenstädt, H; Reuter, S; Stock, CM; Telgmann, RG1

Reviews

1 review(s) available for fulvestrant and metoprolol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for fulvestrant and metoprolol

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
    Clinical and experimental pharmacology & physiology, 2006, Volume: 33, Issue:8

    Topics: Adrenergic beta-Antagonists; Benzopyrans; Cells, Cultured; Endothelial Cells; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Ethanolamines; Fluorescein; Fulvestrant; Humans; Immunohistochemistry; Indicators and Reagents; Metoprolol; Microscopy, Fluorescence; Nebivolol; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Propanolamines; Protein Transport; Receptors, Adrenergic, beta-3; Receptors, Estrogen; Serine; Time Factors; Umbilical Veins; Vasodilator Agents

2006
Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study.
    Journal of hypertension, 2009, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adrenergic beta-Antagonists; Antihypertensive Agents; Arginine; Benzopyrans; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Size; Dose-Response Relationship, Drug; Drug Combinations; Elasticity; Endothelial Cells; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Ethanolamines; Female; Fulvestrant; Genes, Reporter; Humans; Metoprolol; Nanotechnology; Nebivolol; Nitric Oxide; Nitrites; Tamoxifen; Time Factors; Transfection

2009